U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07140640) titled 'Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery: A Risk-Stratified Randomized Controlled Trial.' on Aug. 22.
Brief Summary: Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery: A Risk-Stratified Randomized Controlled Trial.
Study Start Date: Sept. 15
Study Type: INTERVENTIONAL
Condition:
Cesarean Section Complications
Intervention:
DRUG: Hyperbaric Bupivacaine HCl 0.5% 12.5 mg
1- Standard dose group: receiving the typical dose of hyperbaric bupivacaine (12.5 mg hyperbaric bupivacaine + 25 mcg fentanyl).
DRUG:...